Corepharma TECH Spółka z Ograniczoną Odpowiedzialnością (KRS 0001087480, NIP 8971933827) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. Corepharma TECH operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since February 12, 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Corepharma TECH
Identity
- Name
- Corepharma TECH Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- February 12, 2024
- Registry status as of
- July 10, 2026
- Latest entry
- July 10, 2026
- Founding act
- 09.02.2024 R.
Articles of association history (2)
- February 9, 2024: 09.02.2024 R.
- August 20, 2024: 20.08.2024 R., REPERTORIUM A NUMER 2090/2024, NOTARIUSZ SŁAWOMIR SZAPIACZAN, KANCELARIA NOTARIALNA W SZCZECINIE AL. WYZWOLENIA 103/1, ZMIANA UMOWY: NADANO NOWE BRZMIENIE CAŁEJ UMOWY SPÓŁKI : §1 - §21.
Activities
Other activities
Address and contact
- Address
- UL. DUŃSKA, 9, D173, 54-427, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-81715-28589-ATCRU-22
Operational status - Corepharma TECH
Founded
February 12, 2024
2 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
Shareholders
2
shareholders
Board
1 person
Proxies: 1
Registry entries
11
latest: July 10, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Board and connected people - Corepharma TECH
People holding roles at Corepharma TECH according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Filip Zbigniew MajewskiBoard member, Shareholder, Commercial proxy
- Marcin HolukBoard member, Shareholder
- Roksana CiesielskaBoard member, Shareholder
- Konrad Stefan OlechShareholder, Commercial proxy
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Corepharma TECH.
No ratings
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.